12:00 AM
 | 
May 07, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

BI 201335: Additional Phase IIb data

Additional data from the open-label Phase IIb SOUND-C2 trial in 362 treatment-naïve patients with chronic HCV genotype 1 infection showed that 61% of patients receiving once-daily 120 mg BI 201335 plus thrice-daily 600 mg BI 207127 and ribavirin for 28 weeks achieved an SVR 12 weeks after the end of treatment. Additionally, 68% of patients receiving once-daily 120 mg BI 201335 plus twice-daily 600 mg...

Read the full 312 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >